Translational medicine is a field that continues to grow rapidly. Encouraging, supporting, and developing both basic translational research and its therapeutic application is essential to building a strong foundation in science. This webinar will focus on what Denmark is doing in the area of translational medicine to advance research, strengthen ties between academia and industry, and provide a fertile environment for innovation and the practical application of new discoveries. Discussion will cover government initiatives (Danish and European Union) to support translational medicine, as well as the infrastructure that has been put in place within Denmark to support and nurture domestic and foreign investment in this research.
During this webinar our panelists will:
- Discuss the importance of translational research and its impact on scientific discovery and drug development within Denmark
- Outline government and other programs that encourage partnerships between academic institutions and industry
- Talk about the potential advantages for companies of relocation to Denmark to carry out translational research–related work
- Answer your questions live!
Peter Kurtzhals, Ph.D.
Novo Nordisk A/S
Dr. Peter Kurtzhals joined Novo Nordisk in 1990. Prior to this, Dr. Kurtzhals worked as an assistant professor at The Danish University of Pharmaceutical Sciences, where he obtained his M.Sc. and Ph.D. degrees. He has held positions as principal scientist in the insulin research group at Novo Nordisk, as a visiting scientist at the Joslin Diabetes Center, and Harvard Medical School in Boston, and as head of diabetes biology at Novo Nordisk. He was appointed vice president and head of discovery biology in 2000 and senior vice president and member of Novo Nordisk’s Senior Management Board in 2001. Dr. Kurtzhals has been the scientific coordinator for Novo Nordisk's insulin analogue projects, including insulin aspart and insulin detemir. He is currently senior vice president and head of diabetes research at Novo Nordisk A/S. Dr. Kurtzhals is chairman of The Committee on Research Policy, The Danish Association of the Pharmaceutical Industry, and a member of the Research Director Group at European Federation of Pharmaceutical Industries and Associations. He is also a member of the board of The Danish University of Pharmaceutical Sciences and of the board of Steno Diabetes Center.
Lars Arendt-Nielsen, Dr.Med.Sci., Ph.D.
Professor Lars Arendt-Nielsen (doctor of medical science, Ph.D.) is founder and director of the international Center for Sensory-Motor Interaction at Aalborg University in Denmark. After a number of years in London as a postgraduate student at University College and as a research fellow at the National Hospital for Nervous Diseases, Dr. Arendt-Nielsen returned to Denmark where he earned both of his advanced degrees. He has been guest professor at the National Institute for Physiological Sciences, Okasaki, Japan, and Boston University, School of Medicine, as well as honorary professor at Xian Jiaotong University, School of Medicine, China, and University of Bern, Medical Faculty, Switzerland. Dr. Arendt-Nielsen’s research focuses on translational pain research, pain assessment in skin, muscles, and viscera, the development of human biomarkers for screening of new analgesic compounds in humans, and proof-of-concept studies on new analgesic and anti-inflammatory compounds. Besides carrying out experimental and clinical pain studies, Dr. Arendt-Nielsen’s unit also helps companies translate basic preclinical findings into clinical trials. Dr. Arendt-Nielsen has delivered over 210 keynote lectures at international meetings and seminars and published more than 750 papers on experimental and clinical pain research in international peer-reviewed journals.
Liselotte Højgaard, M.D., Dr.Med.Sci.
Dr. Liselotte Højgaard was born in Denmark and educated there, as well as in the United Kingdom and Switzerland. She received both her M.D. and Doctor of Medical Sciences (DMSc) degrees from Copenhagen University. Dr. Højgaard is currently head of department, director, clinical physiology and nuclear medicine and PET and cyclotron unit at Rigshospitalet, University of Copenhagen, and professor in medical technology in science and education in the Faculty of Health Sciences at Copenhagen University, as well as at the Technical University of Denmark (DTU). In addition to having over 150 peer-reviewed publications, Dr. Højgaard has also acted as both assistant editor (1991-1996) and editor-in-chief (1996-2002) of The Danish Medical Journal. She is also chair of The Standing Committee of the European Medical Research Councils at the European Science Foundation (since 2006), member of the Science Advisory Board for the European Science Foundation (since 2007), member of the Science Advisory Board for the Innovative Medicines Initiative (since 2008), member of the FP7 Advisory Board in Medicine to the EC Commisionaire for Research (since 2008), and member of the Conseil d’Administration of 2009, INSERM, L’Institut National de la sante et de la recherches medicales, Frankrig.
Niels Porksen, M.D., D.Sc.
Eli Lilly & Company
Dr. Niels Porksen studied for his degree in medicine at Aarhus University in Denmark, after he completed his medical training in endocrinology and internal medicine at Aarhus University Hospital. Following two years as a research fellow at the Mayo Clinic in Rochester, Minnesota, Dr. Porksen returned to Aarhus University to pursue a further research fellowship, staying on to complete his Doctor of Science (Ph.D.) degree. In 2002, Dr. Porksen joined Eli Lilly and Company at its Indianapolis, Indiana, campus where he is currently director of global external research and development, covering research from target identification through to launched products. During his career, Dr. Porksen has published widely in respected peer-reviewed publications and has given invited talks worldwide.
Moderator: Sean Sanders, Ph.D.
Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Editor for Custom Publishing for the journal Science and Program Director for Outreach.
For information related to this webinar, go to: www.investindk.com